止吐注射 (antiemetics IV) Prevention of chemotherapy-induced nausea and vomiting; prevention of acute (highly-emetogenic therapy) as well as acute and delayed (moderately-emetogenic therapy) nausea and vomiting.

Selective 5-HT3 receptor antagonist, blocking serotonin, both on vagal nerve terminals in the periphery and centrally in the chemoreceptor trigger zone.

Protein binding: ∼ 62%; Metabolism: ∼ 50% metabolizd via CYP enzymes to inactive metabolites; Excretion: Urine (40% as unchanged drug); feces (5%-8%); Elimination half-life: ∼ 40 hrs.

Hypersensitivity to palonosetron or any component of the formulation

B

Excretion in breast milk unknown/not recommended

Headache, constipation, hyperkalemia, weakness.

0.25 mg as a single dose use, 30 minutes prior to the start of chemotherapy administration, IV infuse over 30 seconds. Flush I.V. line with NS prior to and following administration.

do not mix with other drugs